Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 4, 2005. The report details changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADSs) resulting from share allocation arrangements, dividend reinvestment plans, and employee trust transactions.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director shareholdings rather than consolidated financial performance.
Material Changes
Material changes reported include:
- Non-Executive Director Awards: Provisional allocations of Ordinary Shares and ADSs were made on December 31, 2004, for the service period of October 1 to December 31, 2004.
- Dividend Reinvestment: Additional Ordinary Shares and ADSs were allocated to Non-Executive Directors through the annual reinvestment of dividends paid throughout 2004.
- Employee Trust Transfer: On December 23, 2004, the GSK Trust transferred 10,620 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Plan Movement: As of December 31, 2004, the GlaxoSmithKline US Retirement Savings Plan held 18,630,305 Ordinary Share ADRs, a decrease from 18,699,989, at an average price of $46.55.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is a compliance report regarding director share interests.
Key Facts for Investor Verification
- Verify the total number of shares and ADSs allocated to specific Non-Executive Directors under the 2004 service period and dividend reinvestment plans.
- Confirm the impact of the 10,620 share transfer from the GSK Trust to the SmithKline Beecham Employee Share Option Plan 1991.
- Note the reduction in ADR holdings within the US Retirement Savings Plan to 18,630,305 shares.
- Identify directors with potential interests in the GSK Trust and US Retirement Plan, including Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe.